Slow-acting basal insulin, typically injected daily, can help stabilize glucose levels between meals in individuals with diabetes. But results from a phase 3 clinical trial found that efsitora alfa (efsitora), a new insulin designed to be injected once a week, is as safe and effective as other long-acting injections.
